These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26079332)

  • 61. Active surveillance, quality of life, and cancer-related anxiety.
    Klotz L
    Eur Urol; 2013 Jul; 64(1):37-9. PubMed ID: 23433806
    [No Abstract]   [Full Text] [Related]  

  • 62. Treatment Trends for Prostate Cancer.
    Voog JC; Efstathiou JA
    JAMA; 2015 Nov; 314(18):1976-7. PubMed ID: 26547472
    [No Abstract]   [Full Text] [Related]  

  • 63. Re: Trends in Management for Patients with Localized Prostate Cancer, 1990-2013.
    Penson DF
    J Urol; 2016 Feb; 195(2):353-4. PubMed ID: 26852976
    [No Abstract]   [Full Text] [Related]  

  • 64. Prostate cancer: Growth of AS in the USA signals reduction in overtreatment.
    Murphy DG; Loeb S
    Nat Rev Urol; 2015 Nov; 12(11):604-5. PubMed ID: 26390970
    [No Abstract]   [Full Text] [Related]  

  • 65. Reply from authors re: Laurence Klotz. Active surveillance, quality of life, and cancer-related anxiety. Eur Urol 2013;64:37-9: active surveillance: risk and protective factors for quality of life.
    Bellardita L; Valdagni R; Rancati T
    Eur Urol; 2013 Jul; 64(1):39-40. PubMed ID: 23465522
    [No Abstract]   [Full Text] [Related]  

  • 66. The evolving standards of active surveillance monitoring.
    Albertsen PC
    Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):215. PubMed ID: 36085497
    [No Abstract]   [Full Text] [Related]  

  • 67. Urological cancer: management of patients with prostate cancer: evolution towards a risk-stratified approach.
    Sidaway P
    Nat Rev Clin Oncol; 2015 Sep; 12(9):503. PubMed ID: 26215045
    [No Abstract]   [Full Text] [Related]  

  • 68. Does delaying prostate cancer treatment miss the window of curability?
    Loeb S
    Eur Urol; 2013 Aug; 64(2):216-7; discussion 217-8. PubMed ID: 23619388
    [No Abstract]   [Full Text] [Related]  

  • 69. Observation versus initial treatment for prostate cancer.
    Pinsky P
    Ann Intern Med; 2013 Oct; 159(8):574. PubMed ID: 24126652
    [No Abstract]   [Full Text] [Related]  

  • 70. Cost effectiveness of treatment options for early prostate cancer: can we put the puzzle pieces together?
    Xie F
    Eur Urol; 2013 Feb; 63(2):411-2. PubMed ID: 23177080
    [No Abstract]   [Full Text] [Related]  

  • 71. Active Surveillance for Low-Risk Cancers - A Viable Solution to Overtreatment?
    Haymart MR; Miller DC; Hawley ST
    N Engl J Med; 2017 Jul; 377(3):203-206. PubMed ID: 28723330
    [No Abstract]   [Full Text] [Related]  

  • 72. A Roadmap for Improving the Management of Favorable Risk Prostate Cancer.
    Auffenberg GB; Lane BR; Linsell S; Brachulis A; Ye Z; Rakic N; Montie J; Miller DC; Cher ML
    J Urol; 2017 Dec; 198(6):1220-1222. PubMed ID: 28782516
    [No Abstract]   [Full Text] [Related]  

  • 73. Observation versus initial treatment for prostate cancer.
    Hayes JH; Barry MJ; McMahon PM
    Ann Intern Med; 2013 Oct; 159(8):574. PubMed ID: 24126653
    [No Abstract]   [Full Text] [Related]  

  • 74. Large variation in conservative management of low-risk prostate cancer in Australia and New Zealand.
    Ong WL; Thangasamy I; Murphy D; Pritchard E; Evans S; Millar J; Chalasani V; Rashid P; Winter M; Vela I; Pryor D; Mark S; Lawrentschuk N
    BJU Int; 2022 Jun; 130 Suppl 1(Suppl 1):17-19. PubMed ID: 35076135
    [No Abstract]   [Full Text] [Related]  

  • 75. Re: Long-term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience.
    Villers A; Olivier J
    Eur Urol; 2020 Jul; 78(1):112. PubMed ID: 32389440
    [No Abstract]   [Full Text] [Related]  

  • 76. [Not Available].
    Steurer J
    Praxis (Bern 1994); 2016 Nov; 105(23):1391-1392. PubMed ID: 27854171
    [No Abstract]   [Full Text] [Related]  

  • 77. "Real-world" Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer.
    Weiner AB; Schaeffer EM; Eggener SE
    Eur Urol; 2018 Dec; 74(6):708-709. PubMed ID: 30224197
    [No Abstract]   [Full Text] [Related]  

  • 78. Real-time Watchful Surveillance Looks Like Active Waiting.
    Bangma C; Roobol M
    Eur Urol; 2017 Dec; 72(6):908-909. PubMed ID: 28822584
    [No Abstract]   [Full Text] [Related]  

  • 79. Active Surveillance Discussion for Low-risk Prostate Cancer: Patients' Preferences and Counseling Techniques.
    Ahmad AE; Finelli A
    Eur Urol; 2017 Jun; 71(6):872-873. PubMed ID: 28162816
    [No Abstract]   [Full Text] [Related]  

  • 80. Editorial comment.
    Adamy A
    J Urol; 2013 Dec; 190(6):2045-6. PubMed ID: 24055081
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.